Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Towards clinically translatable NIR fluorescence molecular guidance for colonoscopy.
Garcia-Allende PB, Glatz J, Koch M, Tjalma JJ, Hartmans E, Terwisscha van Scheltinga AG, Symvoulidis P, van Dam GM, Nagengast WB, Ntziachristos V. Garcia-Allende PB, et al. Among authors: terwisscha van scheltinga ag, van dam gm. Biomed Opt Express. 2013 Dec 4;5(1):78-92. doi: 10.1364/BOE.5.000078. eCollection 2013 Dec 4. Biomed Opt Express. 2013. PMID: 24466478 Free PMC article.
Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection.
Tjalma JJ, Garcia-Allende PB, Hartmans E, Terwisscha van Scheltinga AG, Boersma-van Ek W, Glatz J, Koch M, van Herwaarden YJ, Bisseling TM, Nagtegaal ID, Timmer-Bosscha H, Koornstra JJ, Karrenbeld A, Kleibeuker JH, van Dam GM, Ntziachristos V, Nagengast WB. Tjalma JJ, et al. Among authors: van herwaarden yj, terwisscha van scheltinga ag, van dam gm. J Nucl Med. 2016 Mar;57(3):480-5. doi: 10.2967/jnumed.115.166975. Epub 2015 Dec 17. J Nucl Med. 2016. PMID: 26678613 Free article.
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schröder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG. Terwisscha van Scheltinga AG, et al. Among authors: van dam gm. J Nucl Med. 2011 Nov;52(11):1778-85. doi: 10.2967/jnumed.111.092833. Epub 2011 Oct 11. J Nucl Med. 2011. PMID: 21990576 Free article.
Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.
Koch M, de Jong JS, Glatz J, Symvoulidis P, Lamberts LE, Adams AL, Kranendonk ME, Terwisscha van Scheltinga AG, Aichler M, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WP, Van der Wall E, Garcia-Allende PB, van Diest PJ, de Vries EG, Walch A, van Dam GM, Ntziachristos V. Koch M, et al. Among authors: van der wall e, van diest pj, terwisscha van scheltinga ag, van dam gm, van der vegt b. Cancer Res. 2017 Feb 1;77(3):623-631. doi: 10.1158/0008-5472.CAN-16-1773. Epub 2016 Nov 22. Cancer Res. 2017. PMID: 27879266
Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM. Lamberts LE, et al. Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi: 10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28119364 Clinical Trial.
Feasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography.
Golestani R, Zeebregts CJ, Terwisscha van Scheltinga AG, Lub-de Hooge MN, van Dam GM, Glaudemans AW, Dierckx RA, Tio RA, Suurmeijer AJ, Boersma HH, Nagengast WB, Slart RH. Golestani R, et al. Among authors: terwisscha van scheltinga ag, van dam gm. Mol Imaging. 2013 Jun;12(4):235-43. Mol Imaging. 2013. PMID: 23651501
Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use.
Ter Weele EJ, Terwisscha van Scheltinga AG, Linssen MD, Nagengast WB, Lindner I, Jorritsma-Smit A, de Vries EG, Kosterink JG, Lub-de Hooge MN. Ter Weele EJ, et al. Among authors: terwisscha van scheltinga ag. Eur J Pharm Biopharm. 2016 Jul;104:226-34. doi: 10.1016/j.ejpb.2016.05.008. Epub 2016 May 12. Eur J Pharm Biopharm. 2016. PMID: 27179587
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA. Terwisscha van Scheltinga AG, et al. J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10. J Nucl Med. 2014. PMID: 24614223 Free article.
Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
Warnders FJ, Waaijer SJ, Pool M, Lub-de Hooge MN, Friedrich M, Terwisscha van Scheltinga AG, Deegen P, Stienen SK, Pieslor PC, Cheung HK, Kosterink JG, de Vries EG. Warnders FJ, et al. Among authors: terwisscha van scheltinga ag. J Nucl Med. 2016 May;57(5):812-7. doi: 10.2967/jnumed.115.168153. Epub 2016 Feb 4. J Nucl Med. 2016. PMID: 26848172 Free article.
34 results